An anti-HIV strategy combining chemotherapy and therapeutic vaccination

被引:17
作者
Rosenwirth, B
Bogers, WMJM
Nieuwenhuis, IG
Ten Haaft, P
Niphuis, H
Kuhn, EM
Bischofberger, N
Erfle, V
Sutter, G
Berglund, P
Liljestrom, P
Uberla, K
Heeney, JL
机构
[1] Biomed Primate Res Ctr, Dept Virol, NL-2280 GH Rijswijk, Netherlands
[2] Biomed Primate Res Ctr, Dept Anim Sci, NL-2280 GH Rijswijk, Netherlands
[3] Gilead Sci Inc, Foster City, CA 94404 USA
[4] GSF Forschungszentrum Umwelt & Gesundheit GMBH, Munich, Germany
[5] Karolinska Inst, Microbiol & Tumorbiol Ctr, Stockholm, Sweden
[6] Swedish Inst Infect Dis Control, Dept Vaccine Res, Stockholm, Sweden
[7] Univ Leipzig, Inst Virol, Leipzig, Germany
关键词
SHIV; macaques; PMPA; anti-retroviral therapy; vaccines;
D O I
10.1111/j.1600-0684.1999.tb00270.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Combination chemotherapy using potent anti-retroviral agents has led to significant advances in the clinical management of human immunodeficiency virus (HIV) disease. However, the emergence of multiple drug-resistant mutants, the high need for compliance to adhere to demanding drug-dosing schemes, and the remaining toxic side-effects of drugs make the perspective of life-long treatment unattractive and possibly unrealistic. Therefore, means must be sought to shorten the time span during which treatment is necessary. Such means could be to stimulate an efficient immune response during the period of low virus load and restored CD4(+) cell levels, which might be capable of keeping the virus under long-lasting control after treatment is stopped. Here we tested this concept of combined chemotherapy/therapeutic vaccination in a non-human primate model. Rhesus macaques chronically infected with the chimeric simian/human immunodeficiency virus (SHIV) containing the HIV type 1 (HIV-1) HXBc2 gene for reverse transcriptase (RT) in the genomic background of simian immunodeficiency virus (SIV)(mac239) (RT-SHIV) were treated with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA), a potent anti-HIV drug. When virus load had decreased significantly, we immunized with SIV genes env, gag/pol, rev, tat, and nef inserted in two different expression vector systems. Four weeks after the second immunization, drug treatment was stopped. Animals were monitored to determine if virus load stayed low or if it increased again to the original levels and if CD4(+) T-cell levels remained stable. Humoral and cellular immune responses were also measured. This combined chemotherapy/therapeutic vaccination regimen induced a significant reduction in the steady-state level of viremia in one out of two chronically infected rhesus macaques. Chemotherapeutic treatment alone did not achieve reduction of viremia in two chronically infected animals. The nature of the immune responses assumed to have been induced by vaccination in one out of the two monkeys remains to be elucidated.
引用
收藏
页码:195 / 205
页数:11
相关论文
共 27 条
[21]  
Morris-Jones S, 1997, Expert Opin Investig Drugs, V6, P1049, DOI 10.1517/13543784.6.8.1049
[22]   In vitro p24 antigen-stimulated lymphocyte proliferation and β-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune) [J].
Moss, RB ;
Wallace, MR ;
Lanza, P ;
Giermakowska, W ;
Jensen, FC ;
Theofan, G ;
Chamberlin, C ;
Richieri, SP ;
Carlo, DJ .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1998, 5 (03) :308-312
[23]   Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in Incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE™) in human immunodeficiency virus type-1 seropositive subjects [J].
Moss, RB ;
Giermakowska, W ;
Lanza, P ;
Turner, JL ;
Wallace, MR ;
Jensen, FC ;
Theofan, G ;
Richieri, SP ;
Carlo, DJ .
VIRAL IMMUNOLOGY, 1997, 10 (04) :221-228
[24]  
Moyle G J, 1997, Expert Opin Investig Drugs, V6, P943, DOI 10.1517/13543784.6.8.943
[25]   Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation [J].
Pakker, NG ;
Notermans, DW ;
de Boer, RJ ;
Roos, MTL ;
de Wolf, F ;
Hill, A ;
Leonard, JM ;
Danner, SA ;
Miedema, F ;
Schellekens, PTA .
NATURE MEDICINE, 1998, 4 (02) :208-214
[26]   A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects [J].
Peters, BS ;
Cheingsong-Popov, R ;
Callow, D ;
Foxall, R ;
Patou, G ;
Hodgkin, K ;
Weber, JN .
JOURNAL OF INFECTION, 1997, 35 (03) :231-235
[27]  
SCHINAZI RF, 1996, INT ANTIVIRAL NEWS, V4, P95